Poster
Pharmacological inhibition of MAP4K1 with BLU2069 and BLU6348 supports previously reported findings in MAP4K1 knock-out and kinase-dead knock-in mice
Author
Kerrie Faia
Condition
Cancer
Drug target
MAP4K1
Drug moa
Inhibition of MAP4K1 to enhance intratumoral immune cell activation and reduce tumor burden
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-AACR-2021-BLU-852-Cancer-Immunotherapy-Poster.pdf
2 organizations
1 product
Product
BLU2069, BLU6348Organization
Roche Innovation CenterOrganization
Blueprint Medicines